Lewes, DE -- (SBWIRE) -- 07/29/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Amarin Corporation plc (ADR) (NASDAQ:AMRN), the Medicines Company (NASDAQ:MDCO), Orexigen Therapeutics, Inc. (NASDAQ:OREX), Endo Health Solutions Inc (NASDAQ:ENDP)
Amarin Corporation plc (ADR) (NASDAQ:AMRN) increased 0.95% and closed at $5.31 on a traded volume of 3.34 million shares, in comparison to 3.74 million shares of average trading volume. So far this year, the stock is down over -64.97%.
The company has a total market capitalization of $798.16 million and its total outstanding shares are 150.31 million.
Will AMRN Continue To Move Higher? Find Out Here
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids.
The Medicines Company (NASDAQ:MDCO) soared 3.37% and closed at $30.68 on a traded volume of 1.02 million shares, whereas its average trading volume is 807,174 million shares. In the last three months, the stock is down -8.17%. The Intra-day range for the stock is $29.09 and $30.81.
Will MDCO Continue To Move Higher? Find Out Here
The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) jumped up 4.05% and closed at $7.45. So far in three months, the stock is up 17.88%. The 52-week range for the stock is $3.76 and $7.79 and during the previous trading session the stock touched its highest price at $7.79. Its introductory price for the day was $7.16, with the overall traded volume of 4.50 million shares.
Will OREX Continue To Move Higher? Find Out Here
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include Contrave, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic, which has completed Phase II clinical trials
Endo Health Solutions Inc (NASDAQ:ENDP), after opening its shares at the price of $37.53, jumped up 0.82% to close at $383.01 for the day. The stock moved on a traded volume of 1.45 million shares, in comparison to 1.48 million shares of average trading volume.
The 52-week range for the stock is $25.00 and $39.90 and during the previous trading session the stock touched its highest price at $38.12. Its introductory price for the day was $37.53.
Will ENDP Continue To Move Higher? Find Out Here
Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel for pain, urology, endocrinology, and oncology.
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at:http://leadingstockalerts.com/disclaimer/